Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study]
Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group
This PHASE3 trial investigates Lymphoma and is currently completed. German High-Grade Non-Hodgkin's Lymphoma Study Group leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Apr 2019 — May 2019 [monthly]
Completed PHASE3
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Nov 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- German High-Grade Non-Hodgkin's Lymphoma Study Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Augsburg, Germany , Bayreuth, Germany , Berlin, Germany , Bielefeld, Germany , Bochum, Germany , Braunschweig, Germany , Bremen, Germany , Chemnitz, Germany , Cologne, Germany and 59 more locations